分期2.0:优化跨诊断临床分期框架以提升青年精神卫生的可靠性与实用性
本文为健康政策类文章,国际工作组指出跨诊断临床分期框架在青年精神卫生研究与实践中的挑战,提出引入「分期内异质性」概念,并建议按临床精神病理学和分期修饰因子定义分期,将修饰因子分为进展相关与扩展相关两类,以优化框架的可靠性、记录一致性和临床效用。
要点
- 全球75%的抑郁、双相和精神病性障碍在25岁前起病,常以非特异性症状或衰减临床综合征为先兆。
- 跨诊断临床分期框架在确定最优治疗和记录共病精神病理及疾病轨迹方面存在不确定性。
- 建议引入分期内异质性,按临床精神病理学和分期修饰因子(进展相关与扩展相关)定义分期。
核心结论
- 国际工作组提出优化跨诊断临床分期框架,引入分期内异质性概念并按临床精神病理学和分期修饰因子定义分期,以提升可靠性、记录一致性和临床效用。
研究设计与样本
- 本文为健康政策类文章,由国际工作组撰写,基于全球75%的抑郁、双相和精神病性障碍在25岁前起病这一背景,分析跨诊断临床分期框架在临床研究与实践中的挑战并提出优化建议。
主要发现
- 全球75%的抑郁、双相和精神病性障碍在25岁前起病,且这些障碍常以非特异性症状或衰减临床综合征为先兆。
- 确定新兴精神障碍的最优治疗干预存在困难,且对共病精神病理和疾病轨迹的考量存在不确定性,促使许多青年精神卫生服务采用跨诊断临床分期框架。
- 工作组指出跨诊断分期框架在临床研究与实践中的应用挑战,并提出引入分期内异质性概念,建议按临床精神病理学和分期修饰因子定义分期。
- 建议将分期修饰因子分为进展相关因素(即分期转换的潜在预测因子)和扩展相关因素(即与当前表现相关、增加治疗选择复杂性的因素)。
关键数值与推荐
- 建议按临床精神病理学和分期修饰因子定义分期,并将分期修饰因子分为进展相关因素和扩展相关因素两类。
临床怎么用
- 在临床与研究中应用修订后的跨诊断分期框架,纳入分期内异质性、临床精神病理学和分期修饰因子(进展相关与扩展相关)以提升分期可靠性和记录一致性。
局限性
- 本文为健康政策类文章,未报告原始研究数据、样本量或统计检验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Globally, 75% of depressive, bipolar, and psychotic disorders emerge by age 25 years. However, these disorders are often preceded by non-specific symptoms or attenuated clinical syndromes. Difficulties in determining optimal treatment interventions for these emerging mental disorders, and uncertainties about accounting for co-occurring psychopathology and illness trajectories, have led many youth mental health services to adopt transdiagnostic clinical staging frameworks. In this Health Policy paper, an international working group highlights ongoing challenges in applying transdiagnostic staging frameworks in clinical research and practice, and proposes refinements to the transdiagnostic model to enhance its reliability, consistent recording, and clinical utility. We introduce the concept of within-stage heterogeneity and describe the advantages of defining stage in terms of clinical psychopathology and stage modifiers. Using examples from medicine, we discuss the utility of categorising stage modifiers into factors associated with progression (ie, potential predictors of stage transition) and extension (ie, factors associated with the current presentation that add complexity to treatment selection). Lastly, we suggest how it is possible to revise the currently used transdiagnostic staging approach to incorporate these key concepts, and how the revised framework could be applied in clinical and research practice.
引用
- Scott J, Iorfino F, Capon W, et al. Staging 2.0: refining transdiagnostic clinical staging frameworks to enhance reliability and utility for youth mental health. Lancet Psychiatry. 2024. PMID: 38643773. doi:10.1016/S2215-0366(24)00060-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。